highly significantP < 0.0002
55 At 12 months after MSC administration, patients exhibited a highly significant improvement in the primary endpoint (change in LVESV) relative to placebo (−17 mL; P < 0.0002), which was associated with a highly significant improvement in LVEF (+6.2 units; P < 0.0001), myocardial mass (+9.8 g; P = 0.09), and quality of life ( Figure 1 ).